Induction of centrosome and chromosome aberrations by imatinib in vitro

Leukemia

Volumn 19, Issue 9, 2005, Pages 1573-1578

  Fabarius, Alice ^a   Giehl, M ^a   Frank, O ^a   Duesberg, P ^a,b   Hochhaus, A ^a   Hehlmann, R ^a   Seifarth, W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Centrosomes; Chronic myeloid leukemia; Cytogenetics; Genetic instability; Imatinib; Karyotype aberrations

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CLONING; CELL CULTURE; CENTROSOME; CHINESE HAMSTER; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; EXPERIMENTAL DESIGN; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDIAN; KARYOTYPE; MUNTJAC; MYELOID LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN FIBROBLAST; SPECIES DIFFERENCE; STEM CELL; TUMOR CELL; ANIMAL; CHEMICALLY INDUCED DISORDER; CRICETULUS; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; HAMSTER; PATHOLOGY; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CENTROSOME; CHROMOSOME ABERRATIONS; CRICETINAE; CRICETULUS; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; MUNTJACS; PIPERAZINES; PYRIMIDINES; TIME FACTORS;

EID: 26944454898     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403861     Document Type: Article

References (43)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
3. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
4. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440-2448.
5. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-336.
6. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-3132.
7. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
8. Izumi T, Imagawa S, Hatake K, Miura Y, Ariyama T, Inazawa J et al. Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive CML. Int J Hematol 1996; 64: 73-77.
9. Ohtsuka E, Kikuchi H, Abe Y, Moriyama K, Ohno E, Hirota K et al. Acute myeloblastic leukaemia without Philadelphia chromosome developing after interferon therapy for chronic myelocytic leukemia with Philadelphia chromosome. Br J Haematol 1995; 90: 951-953.
10. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390-1395.
11. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435-441.
12. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C et al. France Intergroupe pour la Leucemie Myeloide Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-1346.
13. Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
14. Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005; 19: 460-463.
15. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al. Occurence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461-463.
16. O'Dwyer ME, Gaffer KM, Loriaux M, Druker BJ, Olson SB, Magenis RE et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481-487.
17. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center. Cancer 2005; 103: 1659-1669.
18. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005; 19: 1192-1197.
19. Kramer A. Centrosome aberrations-hen or egg in cancer initiation and progression? Leukemia 2005; 19: 1142-1144.
20. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib, mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogeneous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
21. Yerganian G, Leonard M. Maintenance of normal in situ chromosomal features in long-term tissue cultures. Science 1961; 33: 1600-1601.
22. Ray M, Mohandas T. Proposed banding nomenclature for the Chinese hamster chromosomes (Cricetulus griseus). Cytogenet Cell Genet 1976; 16: 83-91.
23. Vig BK, Hallett WH. 5-Azacytidine- and Hoechst-induced aneuploidy in Indian muntjac. Mutat Res 2000; 466: 79-86.
24. Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B et al. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005; 19: 458-460.
25. Casali M, Truglio F, Milone G, Di Raimondo F, Parrinello G, Maserati E et al. Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1992; 4: 269-270.
26. Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M et al. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosomes Cancer 1993; 6: 255-256.
27. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.
28. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan ZM et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 1997; 386: 732-735.
29. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523.
30. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998; 273: 3799-3802.
31. Fabarius A, Hehlmann R, Duesberg PH. Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 2003; 143: 59-72.
32. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976-980.
33. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094-1099.
34. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003; 70: 231-234.
35. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
36. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
37. Bertrand P, Lambert S, Joubert C, Lopez BS. Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells. Oncogene 2003; 22: 7587-7592.
38. Daboussi F, Thacker J, Lopez BS. Genetic interactions between RAD51 and its paralogues for centrosome fragmentation and ploidy control, independently of the sensitivity to genotoxic stresses. Oncogene 2005; 24: 3691-3696.
39. Dodson H, Bourke E, Jeffers LJ, Vagnarelli P, Sonoda E, Takeda S et al. Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J 2004; 23: 3864-3873.
40. Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998; 17: 3309-3318.
41. Ley SC, Marsh M, Bebbington CR, Proudfoot K, Jordan P. Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes. J Cell Biol 1994; 125: 639-649.
42. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24: 287-291.
43. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004; 14: 29-36.